The following stories appear in full on today's Vidyya Medical News Service Web site.
The just completed genome sequence of a deadly type of "Escherichia coli" bacteria suggests that the microbe frequently picks up new DNA from other bacteria and bacterial viruses, including genes that may help explain why this organism is exceptionally virulent and sometimes difficult to treat. The results of this sequencing project, supported by the National Institute of Allergy and Infectious Diseases (NIAID), are reported in the January 25 issue of "Nature".
For more information: Gene Sequence Of Deadly E. Coli Reveals Surprisingly Dynamic Genome
A team of US and African medical researchers has developed a molecular marker that can be used to diagnose individuals with and survey populations for malaria parasites that are resistant to the drug chloroquine. The results of their study, reported in this week's "New England Journal of Medicine", puts a confirmatory clinical stamp on the recent laboratory discovery that tiny
mutations in a single gene of the malaria parasite confer resistance to the drug. In the new study, the marker was found 100 percent of the time in clinical cases of chloroquine-resistant malaria.
For more information: Clinical Study Confirms Single Gene Change In Chloroquine-Resistant Malaria
STI-571, a drug under testing for some types of cancer, received substantial media attention in late 1999. (NBC News referred to the drug simply as a "cancer pill".) STI-571 was initially developed to treat a certain form of leukemia called chronic myelogenous leukemia (CML); the drug showed very promising results in early studies completed in 1999-2000. STI-571 is a part of a growing group of molecularly targeted treatments in which drugs are designed to treat diseases with specific genetic changes. Research studies in 2000 revealed that STI-571 may also be effective in treating certain types of brain and stomach cancers and clinical trials are underway to further determine its usefulness.
For more information: Information For Health Professionals: Background On STI-571 (Glivec)
Declaring that foodborne illness is a serious public health problem, the American Medical Association (AMA), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the USDA's Food Safety & Inspection Service (FSIS) today released a new physician/patient information kit.
For more information: AMA And US Government Release New Foodborne Illness
Viddya presents a small portion of the information released by the AMA and the US Government today. In today's issue you will find a primer of clinical vignettes that are provided for your self-evaluation. The possible situations in these vignettes could present at your practice. The Clinical Considerations booklet and the Foodborne Illnesses Tables that are also part of this primer will provide the information necessary for you to adequately address these "test case" clinical situations.
For more information: Foodborne Illness - What's Your Call? A Primer For Physicians
Today's Vidyya articles are:
As always, we hope you enjoy the issue.